ANX Mast Therapeutics, Inc.

SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, ADVENTRX's chief executive officer, is scheduled to present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo. Mr. Levine is scheduled to present on Tuesday, May 15, 2007 at 12:55 p.m. Central European Summer Time (6:55 a.m. Eastern Daylight Time). The conference takes place May 14 - 15, 2007. The presentation will be webcast live and available for replay via the "Investors" section of the Company's web site at http://www.adventrx.com/ under "Events." The webcast will be made available for replay for 14 days and can be accessed through the same link. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com/. Forward Looking Statement ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866; or Media, Edie DeVine of WeissComm Partners, +1-415-946-1081, for ADVENTRX Pharmaceuticals Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright